Indeed, this nanoparticle efficacy has been demonstrated in vitro, in cell cultures, and in vivo, in xenograft mouse models with both cell lines (DNMT3A-dependent OCI-AML2 and OCI-AML3, FLT3ITD mutated MV4-11) and samples from patients with DNMT3A and FLT3ITDmut AML. This evidence concerns the gene RUNX3 and acute myeloid leukemia.